Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

about

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile

P2860

Q49693513-DB87A638-8BB7-4CF9-8E00-78C895BB0392 Q56888201-17BC69DE-A496-4600-AA90-27AAFC2F5557

P2860

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

Item

http://www.wikidata.org/entity/Q47216309

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@en

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@nl

type

Item

label

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@en

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@nl

prefLabel

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@en

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@nl

P1476

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@en

P2093

Michael B Rothberg

http://www.w3.org/2001/XMLSchema#string

Phuc Le

http://www.w3.org/2001/XMLSchema#string

P2860

The incidence of herpes zoster in a United States administrative database

Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination.

Herpes zoster recurrences more frequent than previously reported.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Long-term persistence of zoster vaccine efficacy

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

P31

scholarly article

P356

10.1001/JAMAINTERNMED.2017.7431

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29297049

http://www.w3.org/2001/XMLSchema#string

P932

5838796

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

about

P2860

P2860

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932